David A. Braun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David A. Braun has a total of 745 co-authors. Here are the top co-authors by number of shared publications:
- Toni K. Choueiri
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
256 shared publications - Sabina Signoretti
Department of Pathology, Brigham and Women’s Hospital, Boston, USA
239 shared publications - Thomas Denize
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts
231 shared publications - David F. McDermott
Harvard Medical School, Boston, Massachusetts
215 shared publications - Valisha Shah
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
174 shared publications - Wanling Xie
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
138 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Elsevier in Cell Reports Medicine
- p. 103114
Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies
- 15 October 2026
- Published by Elsevier in Cell Reports Medicine
- p. 103114
Open AccessPrediction of immunotherapy response using live tumor fragments from routine clinical biopsies
- Open Access
- 7 September 2026
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 31
Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer
- 7 September 2026
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 31
Open AccessReviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 2. List of the antibodies and dyes used for the Multiplex IF assay (panel 2).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 2. List of the antibodies and dyes used for the Multiplex IF assay (panel 2).
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 8. Spearman correlation coefficients between candidate biomarkers.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 8. Spearman correlation coefficients between candidate biomarkers.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 6. ORR and PFS per density of CD8+PD-1+TIM-3-LAG-3- TIL levels (high vs. low) combined with TC PD-L1 status (cut-off ≥1%).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 6. ORR and PFS per density of CD8+PD-1+TIM-3-LAG-3- TIL levels (high vs. low) combined with TC PD-L1 status (cut-off ≥1%).
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 9. ORR and PFS per density of CD8+PD-1+TIM3-LAG3- TILs (high vs low) combined with density of CD163+ TAMs (high vs low).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 9. ORR and PFS per density of CD8+PD-1+TIM3-LAG3- TILs (high vs low) combined with density of CD163+ TAMs (high vs low).
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 3. Demographic and clinical characteristics of patients from the HCRN 16-260 trial included and not included in the study.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 3. Demographic and clinical characteristics of patients from the HCRN 16-260 trial included and not included in the study.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 1. List of the antibodies and dyes used for the Multiplex IF assay (panel 1).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 1. List of the antibodies and dyes used for the Multiplex IF assay (panel 1).
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 5. Association between density of terminally exhausted CD8+ TILs measured as continuous variables and clinical outcomes (ORR, PFS).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 5. Association between density of terminally exhausted CD8+ TILs measured as continuous variables and clinical outcomes (ORR, PFS).
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Figure 5. Comparison of PFS (A) and ORR (B) between HCRN 16-260 trial patients included and not included in the study. 2-sided p-values are shown.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Figure 5. Comparison of PFS (A) and ORR (B) between HCRN 16-260 trial patients included and not included in the study. 2-sided p-values are shown.